Q32 Bio Valuation
Is 0T6G undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0T6G when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 0T6G's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 0T6G's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0T6G?
Key metric: As 0T6G is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 0T6G's PB Ratio? | |
|---|---|
| PB Ratio | 16.3x |
| Book | US$18.30m |
| Market Cap | US$299.04m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | -15.8x |
| Enterprise Value/EBITDA | -3x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 0T6G's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 40.8x | ||
PRTC PureTech Health | 1.6x | -13.0% | UK£408.0m |
OXB Oxford Biomedica | 6.7x | 93.2% | UK£447.3m |
BVXP Bioventix | 16.3x | n/a | UK£195.7m |
FARN Faron Pharmaceuticals Oy | 138.6x | 17.3% | UK£159.6m |
0T6G Q32 Bio | 16.3x | -31.7% | US$299.0m |
Price-To-Book vs Peers: 0T6G is good value based on its Price-To-Book Ratio (16.3x) compared to the peer average (40.8x).
Price to Book Ratio vs Industry
How does 0T6G's PB Ratio compare vs other companies in the GB Biotechs Industry?
Price-To-Book vs Industry: 0T6G is expensive based on its Price-To-Book Ratio (16.3x) compared to the UK Biotechs industry average (2.9x).
Price to Book Ratio vs Fair Ratio
What is 0T6G's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 16.3x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 0T6G's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$25.19 | US$86.33 +242.7% | 12.1% | US$100.00 | US$68.00 | n/a | 6 |
| Nov ’25 | US$47.75 | US$79.83 +67.2% | 21.7% | US$100.00 | US$54.00 | n/a | 6 |
| Oct ’25 | US$41.80 | US$77.80 +86.1% | 23.5% | US$100.00 | US$54.00 | n/a | 5 |
| Sep ’25 | US$39.37 | US$66.00 +67.6% | 30.2% | US$100.00 | US$50.00 | n/a | 4 |
| Aug ’25 | US$37.07 | US$62.25 +67.9% | 35.4% | US$100.00 | US$45.00 | n/a | 4 |
| Jul ’25 | US$17.89 | US$62.25 +248.0% | 35.4% | US$100.00 | US$45.00 | n/a | 4 |
| Jun ’25 | n/a | US$49.67 0% | 7.4% | US$54.00 | US$45.00 | n/a | 3 |
| May ’25 | US$25.90 | US$47.50 +83.4% | 5.3% | US$50.00 | US$45.00 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Formycon
€827.2m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€48.50
7D
4.3%
1Y
-21.3%
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
0ILL
€63.05
7D
1.3%
1Y
13.6%
Regeneron Pharmaceuticals
US$79.4b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$745.63
7D
-2.0%
1Y
-6.4%